$1.30
1.15% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US2307701092
Symbol
CPIX
Sector
Industry

Cumberland Pharmaceuticals Inc. Stock price

$1.30
-0.21 13.67% 1M
-0.65 33.25% 6M
-0.50 27.72% YTD
-0.37 21.99% 1Y
-1.52 53.91% 3Y
-3.58 73.44% 5Y
-3.83 74.71% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.02 1.15%
ISIN
US2307701092
Symbol
CPIX
Sector
Industry

Key metrics

Market capitalization $18.25m
Enterprise Value $22.16m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.59
P/S ratio (TTM) P/S ratio 0.48
P/B ratio (TTM) P/B ratio 0.69
Revenue growth (TTM) Revenue growth -7.05%
Revenue (TTM) Revenue $37.79m
EBIT (operating result TTM) EBIT $-7.83m
Free Cash Flow (TTM) Free Cash Flow $-870.00k
Cash position $17.34m
EPS (TTM) EPS $-0.73
Short interest 0.12%
Show more

Is Cumberland Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Cumberland Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Cumberland Pharmaceuticals Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Cumberland Pharmaceuticals Inc.:

Buy
100%

Financial data from Cumberland Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
38 38
7% 7%
100%
- Direct Costs 11 11
7% 7%
30%
26 26
7% 7%
70%
- Selling and Administrative Expenses 23 23
6% 6%
60%
- Research and Development Expense 5.41 5.41
6% 6%
14%
-1.66 -1.66
14% 14%
-4%
- Depreciation and Amortization 6.17 6.17
37% 37%
16%
EBIT (Operating Income) EBIT -7.83 -7.83
31% 31%
-21%
Net Profit -10 -10
483% 483%
-27%

In millions USD.

Don't miss a Thing! We will send you all news about Cumberland Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cumberland Pharmaceuticals Inc. Stock News

Neutral
Seeking Alpha
27 days ago
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q2 2024 Results Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Molly Aggas - Investor Relations, Dalton Agency A.J. Kazimi - Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Officer Conference Call Participants Operator Good afternoon.
Neutral
PRNewsWire
about one month ago
NASHVILLE, Tenn. , Aug. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2024.
Neutral
PRNewsWire
about one month ago
NASHVILLE, Tenn. , July 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2024 financial results and provide a company update after the market closes on Tuesday, Aug. 6, 2024.
More Cumberland Pharmaceuticals Inc. News

Company Profile

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, and RediTrex. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.

Head office United States
CEO A. Kazimi
Employees 91
Founded 1999
Website www.cumberlandpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today